e-learning
resources
Vienna 2012
Monday, 03.09.2012
COPD: risk factors, biomarkers and diagnosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD
J. Thornton Snider, Y. Luna, K. Wong, J. Zhang, S. Chen, D. Goldman (Los Angeles, East Hanover, United States Of America)
Source:
Annual Congress 2012 - COPD: risk factors, biomarkers and diagnosis
Session:
COPD: risk factors, biomarkers and diagnosis
Session type:
Oral Presentation
Number:
1683
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Thornton Snider, Y. Luna, K. Wong, J. Zhang, S. Chen, D. Goldman (Los Angeles, East Hanover, United States Of America). Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Eur Respir J 2012; 40: Suppl. 56, 1683
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Inhaled corticosteroids and pneumonia mortality in COPD patients
Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019
Year: 2019
Inhaled corticosteroids and pneumonia mortality in COPD patients
Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019
Year: 2019
Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010
Inhaled corticosteroid therapy on admission of hospitalized patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 243s
Year: 2002
Inhaled corticosteroid related pneumonia in real world among the patients with asthma and COPD
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Inhaled steroids prescribing in patients with COPD in the community
Source: Eur Respir J 2001; 18: Suppl. 33, 59s
Year: 2001
Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Inhaled medication use in asthma and COPD Roma/Gypsies patients
Source: Eur Respir J 2005; 26: Suppl. 49, 610s
Year: 2005
Risks of pneumonia in asthmatic patients taking inhaled corticosteroids
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011
Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying?
Source: Eur Respir J 2011; 37: 1-3
Year: 2011
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003
Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia
Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD
Year: 2010
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Inhaled corticosteroids are over prescribed in patients with COPD, attending hospital
Source: Eur Respir J 2006; 28: Suppl. 50, 429s
Year: 2006
Inhaled antibiotic therapy in patients with severe asthma
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<%
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept